• Stock(600222)Hot line:010-61006450

    About Us


    Leadingpharm (stock code: 600222) was established in 2005. It is a high-tech enterprise providing pharmacy pre-clinical research, clinical CRO and CDMO services to the whole world. It has been rated as "China’s Top 10 Pharmaceutical R&D Enterprises "for many years (ranked first in 2019). The company is headquartered in Beijing Zhongguancun High-tech Park and has established New Drug Screening and Testing Platform, Drug Evaluation Platform (animal room, certified by GLP, AAALAC, CNAS), Large Molecule Pilot and Large-scale Production Platform, Small Molecule CMC Research and Production Platform, Cell Technology Platform and Clinical CRO Platform in Lifezhengzhou. The six platforms comply with international standards (FDA, EMA and NMPAGMP) , forming Leadingpharm CXO Whole Industry Chain Service System. The combination of imitation and creation, driven by dual engines, can provide customers with diversified services throughout the pharmaceutical research and development.





    • Company News

    Strategic Cooperation | Leadingpharm has Reached Strategic Cooperation with DASAN Pharmaceutical (Korea)

    On August 26, the strategic signing ceremony between Beijing Leadingpharm Medical and Dashan Pharmaceutical was held in Research Institute of Leadingpharm in Beijing.


    The Biomedicine Integrated R & D Service Base of Beijing Leadingpharm has Landed in Yongchuan, Chongqing

    On August 23, the Smart China EXPO 2021 Key Projects of Investment Promotion and Signing Activities of Major Projects Signing Ceremony was held in Chongqing Yuelai International Convention Center.


    Leadingpharm and China Biology Signed an Agreement of Phase-I Clinical Research on a New Drug for Type 2 Diabetes

    Recently, Leadingpharm signed a cooperation agreement with China Biology on the phase I clinical research project of "insulin secreting peptide fusion protein injection". The project is developed by Lanzhou Institute of biological products of China Biology.